ResMed director Jan De Witte sells 429 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
ResMed Inc. director Jan De Witte sold 429 shares of common stock at $237 per share on November 17, 2026. After the sale, he directly held 3,772 shares. The transaction was conducted under a Rule 10b5-1 plan adopted August 19, 2026.
Insider Trade Summary 10b5-1
Net Seller: 429 shares
Net Sell
1 txn
Insider
De Witte Jan
Role
Director
Sold
429 shs ($102K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | ResMed Common Stock F1 | 429 | $237.00 | $102K |
Holdings After Transaction:
ResMed Common Stock — 3,772 shares (Direct)
Footnotes (1)
- F1. The transaction was conducted under a Rule 10b5-1 plan adopted August 19, 2026.
Key Figures
Shares sold: 429 shares
Sale price: $237 per share
Direct shares after sale: 3,772 shares
3 metrics
Shares sold
429 shares
November 17, 2026
Sale price
$237 per share
November 17, 2026
Direct shares after sale
3,772 shares
After the November 17, 2026 sale
Key Terms
Rule 10b5-1 plan
1 terms
Rule 10b5-1 plan regulatory
"the sale was conducted under a Rule 10b5-1 plan"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.